Qiagen and ID Solutions, Digital PCR for Oncology Studies Partner to increase the lals

Qiagen on Friday (NYSE:Goggle) Digital polymeraz chain reaction (DPCR) chain reaction (DPCR) analysis for oncological research applications has been declared a new trade cooperation and a joint marketing agreement with ID solutions.

Partnership, Qiagen’s Qiagological Survey aims to use Giagen’s global expansion and automation expertise to strengthen Qiagen’s position.

A scientist in a laboratory coat using the latest medical equipment to clean the nucleic acid.

Under the terms of the agreement, ID solutions will produce and supply DPCR analysis specifically for non-clinical research on Qiagen’s Qiacuity platforms. These moments are designed to determine many mutations in cellular DNA, which are formed from plasma and genomical DNA to a cellular DNA. Qiagen first these kits will come to the market in Europe, to other regions with future expansion plans.

The newly added analyzes will complete the current pancakes for the detection of various signs of different types of samples, as well as more than 200 locked nucleic acid (LNA) mutation analysis. For customers, this cooperation has become a requirements for optimized use of non-clinical oncology research, and becomes a period of less than one day a day, and the less the day has become prepared to use. Qiagen (NYSE: GGEN) provides sample-thinking solutions that converted biological examples of biological examples in the Netherlands and international scale.

When we recognize the potential to cultivate a greneware, our beliefs are caused by the fact that some AI shares make higher revenues and a limited number of risks. If you are looking for a EU reserve with more promising and 100x upsideotal potential than qgen, review our report Cheap EU reserves.

Read the next: 30 shares of double in 3 years and Currently 8 secret EU reserves.

Disclosure: No. This article was first published Insayer monkey.